婴幼儿血管瘤循证治疗现状

doi:10.19438/j.cjoms.2022.01.002

中国口腔颌面外科杂志 ›› 2022, Vol. 20 ›› Issue (1): 7-14.doi: 10.19438/j.cjoms.2022.01.002

婴幼儿血管瘤循证治疗现状

郑家伟, 赵泽亮, 陈启铭

上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科,上海交通大学口腔医学院,国家口腔医学中心,国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海 200011

收稿日期:2021-09-20 修回日期:2021-10-18 出版日期:2022-01-20 发布日期:2022-01-20
通讯作者: 郑家伟,E-mail: davidzhengjw@hotmail.com
作者简介:郑家伟（1964-）,男,博士,教授,博士研究生导师
基金资助:
国家自然科学基金（82071130）

Current evidence-based treatment of infantile hemangiomas

ZHENG Jia-wei, ZHAO Ze-liang, CHEN Qi-ming

Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology. Shanghai 200011, China

Received:2021-09-20 Revised:2021-10-18 Online:2022-01-20 Published:2022-01-20

摘要/Abstract

摘要： 婴幼儿血管瘤是儿童期最常见的良性肿瘤,目前主张早期予以干预,以减少并发症和对心理发育的负面影响。随着β受体阻滞剂的成功应用,治疗方法发生了革命性变化,治疗效果也随之提高。本文结合文献分析,基于循证医学证据,概述了婴幼儿血管瘤各种治疗方法的适应证、优缺点和选择依据,以期为临床应用提供指导。

关键词: 婴幼儿血管瘤, 循证治疗, β受体阻滞剂

Abstract: Infantile hemangioma is the most common benign tumor in childhood. Early intervention is currently advocated so as to minimize complications and negative effects on mental development. With the successful application of various β-blockers, the treatment methods have undergone revolutionary changes, and the treatment effect has also been improved. Based on literature review and evidence-based medicine, this article summarized the indications, advantages and disadvantages and selection of various treatment methods for infantile hemangioma, in order to provide guidance for clinical application.

Key words: Infantile hemangioma, Evidence-based treatment, Beta receptor blockers

中图分类号:

R739.8

郑家伟, 赵泽亮, 陈启铭. 婴幼儿血管瘤循证治疗现状[J]. 中国口腔颌面外科杂志, 2022, 20(1): 7-14.

ZHENG Jia-wei, ZHAO Ze-liang, CHEN Qi-ming. Current evidence-based treatment of infantile hemangiomas[J]. China J Oral Maxillofac Surg, 2022, 20(1): 7-14.

参考文献

[1] Kilcline C, Frieden IJ.Infantile hemangiomas: how common are they? a systematic review of the medical literature[J]. Pediatr Dermatol,2008,25(2):168-173.
[2] 郑家伟. 婴幼儿血管瘤“等待观察”的治疗策略应予改变[J].中国口腔颌面外科杂志,2012,10(2):163-164.
[3] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy[J]. N Engl J Med, 2008,358(24):2649-2651.
[4] Moyakine AV, Herwegen B, van der Vleuten CJM. Use of the Hemangioma Severity Scale to facilitate treatment decisions for infantile hemangiomas[J]. J Am Acad Dermatol, 2017,77(5):868-873.
[5] Janmohamed SR, de Waard-van der Spek FB, Madern GC, et al.Scoring the proliferative activity of haemangioma of infancy: the Haemangioma Activity Score (HAS)[J]. Clin Exp Dermatol, 2011,36(7):715-723.
[6] Haggstrom AN, Beaumont JL, Lai JS, et al.Measuring the severity of infantile hemangiomas: instrument development and reliability[J]. Arch Dermatol, 2012,148(2):197-202.
[7] Sebaratnam D, Rodríguez Bandera AI, Wong LF, et al.Infantile hemangioma. part 2: management[J]. Am Acad Dermatol, 2021,85(6):1395-1404.
[8] Overman J, Fontaine F, Wylie-Sears J, et al.R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma[J]. ELife, 2019,8:e43026.
[9] Solman L, Glover M, Beattie PE, et al.Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology 406 consensus guidelines[J]. Brit J Dermatol, 2018,179(3):582-589.
[10] Smithson SL, Rademaker M, Adams S, et al.Consensus statement for the treatment of infantile haemangiomas with propranolol[J]. Australas J Dermatol, 2017,58(2):155-159.
[11] Shah SD, Baselga E, McCuaig C, et al. Rebound growth of infantile hemangiomas after propranolol therapy[J]. Pediatrics, 2016,137(4):e20151754.
[12] Caussé S, Aubert H, Saint-Jean M, et al.Propranolol-resistant infantile haemangiomas[J]. Brit J Dermatol,2013,169(1):125-129.
[13] Zhao ZL, Liu C, Zheng JW, et al.Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients[J]. Ann Transl Med,2021,9(2):116.
[14] 王琦,向波,吉毅,等.普萘洛尔与阿替洛尔治疗婴儿血管瘤的比较研究[J].中华皮肤科杂志,2016,49(10):683-687.
[15] Laurens C, Abot A, Delarue A, et al.Central effects of beta-blockers may be due to oxide and hydrogen peroxide release independently of their ability to cross the blood-brain barrier[J]. Front Neurosci, 2019,13:33.
[16] Aly MM, Hamza AF, Abdel Kader HM, et al.Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma[J]. Eur J Pediatr, 2015,174(11):1503-1509.
[17] Liu C, Zhao Z, Wu H, et al.Effect of combined low-dose oral prednisone with beta-adrenergic receptor antagonists for refractory infantile hemangiomas: retrospective cohort study in 76 patients[J]. Ann Transl Med, 2019,7(23):750.
[18] Gnarra M, Solman L, Harper J, et al.Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome[J]. Br J Dermatol, 2015,173(1):242-246.
[19] Davila-Osorio VL, Iznardo H, Roe E, et al.Propranolol-resistant infantile hemangioma successfully treated with sirolimus[J]. Pediatr Dermatol, 2020,37(4):684-686.
[20] Zaher H, Rasheed H, El-Komy MM, et al.Propranolol versus captopril in the treatment of infantile hemangioma (IH): a randomized controlled trial[J]. J Amer Acad Dermatol, 2016,74(3):499-505.
[21] Wu HW, Liu C, Wang X, et al.Topical application of 0.5% timolol maleate hydrogel for the treatment of superficial infantile hemangioma[J]. Front Oncol,2017,7:137.
[22] M Hill I, Stefanko N, Drolet BA. Comment on "doing the math: a simple approach to topical timolol dosing for infantile hemangiomas"[J]. Pediatr Dermatol, 35(5):698-699.
[23] Danarti R, Ariwibowo L, Radiono S, et al.Topical timolol maleate 0.5% for infantile hemangioma: its effectiveness compared to ultrapotent topical corticosteroids - a single-center experience of 278 cases[J]. Dermatology, 2016,232(5):566-571.
[24] Hartmann F, Lockmann A, Gronemeyer LL, et al.Nd:YAG and pulsed dye laser therapy in infantile haemangiomas: a retrospective analysis of 271 treated haemangiomas in 149 children[J]. J Eur Acad Dermatol Venereol, 2017,31(8):1372-1379.
[25] Jin WW, Tong Y, Wu JM, et al.Observation on the effects of 595- nm pulsed dye laser and 755- nm long-pulsed alexandrite laser on sequential therapy of infantile hemangioma[J]. J Cosmet Laser Ther, 2020,22(3):159-164.
[26] Pandey V, Tiwari P, Sharma SP, et al.Role of intralesional bleomycin and intralesional triamcinolone therapy in residual haemangioma following propranolol[J]. Int J Oral Maxillofac Surg, 2018,47(7):908-912.
[27] Waner M.The surgical management of infantile hemangiomas[J]. Otolaryngol Clin North Am, 2018,51(1):125-131.
[28] Fernández Faith E, Shah S, Witman PM, et al.Clinical features, prognostic factors, and treatment interventions for ulceration in patients with infantile hemangioma[J]. JAMA Dermatol, 2021,157(5):566-572.
[29] Frieden IJ, Püttgen KB, Drolet BA, et al.Management of infantile hemangiomas during the COVID pandemic[J]. Pediatric Dermatol, 2020,37(3):412-418.

婴幼儿血管瘤循证治疗现状

Current evidence-based treatment of infantile hemangiomas

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李晓, 范新东, 郑家伟. 脉管异常的ISSVA分类概要及分子生物学研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(3): 286-290.
[2]	郑家伟, 王绪凯, 秦中平, 范新东, 李凯, 杨耀武, 霍然, 刘少华, 赵吉宏, 汪小勇, 周德凯, 刘学键. 口服普萘洛尔治疗婴幼儿血管瘤中国专家共识（2022版）[J]. 中国口腔颌面外科杂志, 2022, 20(4): 313-319.
[3]	王杞章, 郑家伟. 口服普萘洛尔治疗婴幼儿增殖期血管瘤:英国儿科皮肤病学会共识及临床指南[J]. 中国口腔颌面外科杂志, 2020, 18(6): 548-552.
[4]	顾达, 霍然, 徐广琪, 毕见海, 李尚滨. 局部外用β受体阻滞剂治疗婴幼儿血管瘤的临床应用研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(4): 375-380.
[5]	李红, 周昱川, 龚忠诚, 孙杨, 凌彬. 口服普萘洛尔联合外用盐酸倍他洛尔治疗8例眶周高风险婴幼儿血管瘤的疗效和安全性评价[J]. 中国口腔颌面外科杂志, 2020, 18(3): 264-268.
[6]	宋会新, 林春男, 王田友, 付兆臣. 普萘洛尔治疗婴幼儿血管瘤的作用机制研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(2): 182-185.
[7]	刘学键, 刘志鹏, 武宜雷, 邰茂众. 平阳霉素新剂型瘤体内注射治疗婴幼儿血管瘤203例临床分析[J]. 中国口腔颌面外科杂志, 2019, 17(3): 247-250.
[8]	张凯驰, 徐大朋, 程沫沙, 王绪凯. 马来酸噻吗洛尔和普萘洛尔治疗婴幼儿表浅型血管瘤的疗效分析[J]. 中国口腔颌面外科杂志, 2017, 15(6): 529-533.
[9]	周昱川，凌彬，龚忠诚，许颖捷，陈青立. 外涂盐酸倍他洛尔滴眼液治疗7例表浅型婴幼儿血管瘤疗效观察[J]. 中国口腔颌面外科杂志, 2017, 15(5): 438-441.
[10]	程沫沙，张凯驰，王绪凯. 普萘洛尔治疗溃疡性婴幼儿血管瘤18例临床分析[J]. 中国口腔颌面外科杂志, 2017, 15(3): 264-267.
[11]	王菲楠, 范新东. 放射性核素治疗婴幼儿血管瘤的现状[J]. 中国口腔颌面外科杂志, 2016, 14(5): 471-474.
[12]	彭昊，周国瑜，赵建鑫，沈玲悦，马川. 组织块法建立婴幼儿血管瘤动物模型的实验研究[J]. 中国口腔颌面外科杂志, 2015, 13(6): 486-490.
[13]	王亚飞, 周权, 王忠强. 小剂量盐酸普萘洛尔口服治疗不同月龄婴幼儿血管瘤临床疗效观察[J]. 中国口腔颌面外科杂志, 2015, 13(1): 38-41.
[14]	王佳, 石静, 王绪凯. 0.5%马来酸噻吗洛尔溶液联合普萘洛尔治疗婴幼儿血管瘤的不良反应观察[J]. 中国口腔颌面外科杂志, 2014, 12(6): 539-542.
[15]	郑家伟, 马坤宁, 张凌. 婴幼儿血管瘤药物治疗概述[J]. 中国口腔颌面外科杂志, 2014, 12(1): 1-6.